Cystic Fibrosis Foundation Introduces New Members to Board of Trustees
Gracie Gottlieb | 9 August, 2023
The Cystic Fibrosis Foundation, a global leader in finding a cure for cystic fibrosis, has recently announced changes to its Board of Trustees. The Foundation welcomes Kate O’Donnell, Dodzie Sogah, and Elise Eberwein as new members, each bringing their unique expertise and dedication to support the mission of the CF Foundation.
The CF Foundation's Board of Trustees plays a crucial role in shaping the organization's vision to meet the evolving needs of the CF community. With the addition of these new members, the Foundation aims to further enhance its commitment to all individuals affected by cystic fibrosis.
Kate O’Donnell, MBA, Trustee
Kate O’Donnell has been involved with the CF Foundation as a volunteer for over two decades. She has made significant contributions, co-chairing the 2023 Volunteer Leadership Conference and chairing the Massachusetts/Rhode Island Chapter's Tomorrow's Leaders since 2018. Additionally, Kate serves as the president of the Joey Fund, an organization that has raised millions of dollars on behalf of the CF Foundation. She holds an MBA from Harvard Business School and an AB in English from Harvard University. Currently, Kate works with Belmont Capital, LLC, a venture capital and private equity firm based in Cambridge, Massachusetts.
Dodzie Sogah, PhD, Trustee
Dodzie Sogah has dedicated his career to bridging the gap between business, science, and medicine. As a venture partner at Third Rock Ventures, Dodzie focuses on establishing new life sciences companies that leverage genetic and biological technologies to develop innovative therapies. With his experience in corporate and business development, including his contributions to genetic technology partnerships at Vertex Pharmaceuticals, Dodzie brings valuable insights to the CF Foundation. He earned his PhD in cellular and developmental biology from Harvard Medical School and an AM in molecular and cellular biology and an AB in biochemical sciences from Harvard University.
Elise Eberwein, MBA, Advisor
Elise Eberwein brings extensive experience in the airline industry to the CF Foundation. Throughout her career, she served on the executive leadership team at American Airlines, overseeing various functions such as human resources, communications, and community relations. Her involvement with the CF Foundation includes attending numerous events, including the American Airlines Celebrity Ski, which has raised millions of dollars for the organization. Elise received the Foundation's Jena Award in 2023 for her exceptional volunteerism. She holds an MBA from Colorado State University and a BA in mass communications from Lindenwood University.
The CF Foundation's Board of Trustees and Advisors work collectively to drive the Foundation's mission forward. Their expertise and dedication are vital in making significant advancements in CF research and care. To view the complete list of the CF Foundation's Board of Trustees and Advisors, visit [cff.org](https://www.cff.org/about-us/board-trustees-and-advisors).
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is committed to finding a cure for cystic fibrosis and funds extensive research in the field. Through their support, almost every available CF drug today was made possible. The Foundation is based in Bethesda, Maryland, and is recognized by the National Institutes of Health for its exemplary care center network. As a donor-supported nonprofit organization, the CF Foundation continues to make significant progress in improving the lives of individuals affected by cystic fibrosis. For more information, visit [cff.org](https://www.cff.org/node/1).
In conclusion, the Cystic Fibrosis Foundation's announcement of new members joining its Board of Trustees showcases the organization's dedication to improving the lives of individuals with cystic fibrosis. The addition of Kate O'Donnell, Dodzie Sogah, and Elise Eberwein brings fresh perspectives and expertise to the Foundation, further driving their mission forward. With their collective efforts, the CF Foundation continues to pave the way for advancements in research, care, and support for the CF community.
Other Posts
- When Carrots Met Beverages: A Tale of Two Companies' Leap Towards Growth and Innovation
- Vertex Pharmaceuticals Strengthens Board with Addition of Michel Lagarde
- Navigating Shifts in Investment Strategies: Strategic Advisors' 2023 Portfolio Dynamics
- Great Hill Partners: Pioneering Innovation and Disruption in Mid-Market Private Equity Investment
- Oliver Luxxe Assets LLC Q4 2022 vs. Q1 2023: A Comparative Analysis of Investment Holdings
- Navigating Portfolio Dynamics: A Deep Dive into Sound Income Strategies' Asset Adjustments
- Total Investment Management Inc Q1 2023 vs. Q2 2023 13F Holdings Comparison
- Investing in 2022: A Look at Altman Advisors' Q3 vs Q4 Holdings
- Aldebaran Financial Inc. 13F Holdings: A Q4 2022 vs. Q1 2023 Comparison
- Pacific Global Investment Management Co Q4 2022 vs. Q1 2023 13F Holdings Comparison